Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10218991 | 1.00 | TAS1R3 (0.49) | TAS1R3TAS1R1L3MBTL1HDAC2CYP2C9 | |
| SCHEMBL10218995 | 0.89 | TAS1R3 (0.51) | TAS1R3TAS1R1L3MBTL1HDAC2KMT2A | |
| SCHEMBL10218998 | 0.89 | TAS1R3 (0.51) | TAS1R3TAS1R1L3MBTL1HDAC2KMT2A | |
| SCHEMBL10218976 | 0.85 | ALDH1A1 (0.41) | TAS1R3TAS1R1L3MBTL1KMT2APOLB | |
| SCHEMBL2487959 | 0.85 | TAS1R3 (0.48) | TAS1R3TAS1R1L3MBTL1HDAC2CYP2C9 | |
| SCHEMBL2487219 | 0.85 | TAS1R3 (0.48) | TAS1R3TAS1R1L3MBTL1HDAC2CYP2C9 | |
| SCHEMBL10218978 | 0.85 | ALDH1A1 (0.41) | TAS1R3TAS1R1L3MBTL1KMT2APOLB | |
| SCHEMBL13913176 | 0.85 | TAS1R3 (0.48) | TAS1R3TAS1R1L3MBTL1HDAC2CYP2C9 | |
| SCHEMBL10218983 | 0.85 | ALDH1A1 (0.41) | TAS1R3TAS1R1L3MBTL1KMT2APOLB | |
| SCHEMBL15107352 | 0.81 | TAS1R3 (0.46) | TAS1R3TAS1R1L3MBTL1HDAC2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | TAS1R3 1384/4885TAS1R1 1614/4885L3MBTL1 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.